GlassScriptPhysician profile
Carol Mclean
NPI 1598988248
$2,968.96
in general payments reported to CMS, 2019-2025
23 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.65 · 2022: $120 · 2023: $150 · 2024: $570 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $533.00 | 2025 | Repatha |
| Teva Pharmaceuticals USA, INC. | $338.05 | 2025 | |
| Alexion Pharmaceuticals, INC. | $230.26 | 2024-2025 | Strensiq |
| Sage Therapeutics, LLC | $195.17 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $193.93 | 2025 | |
| Biomerieux INC | $162.00 | 2025 | |
| Novo Nordisk INC | $124.61 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $123.36 | 2025 | Voquezna |
| Ars Pharmaceuticals Operations, INC. | $121.69 | 2025 | Neffy |
| Urovant Sciences INC | $120.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $112.04 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $103.32 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $102.82 | 2025 | |
| Astellas Pharma US INC | $102.18 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $94.50 | 2025 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $82.61 | 2024 | |
| Sanofi-Aventis U.S. LLC | $77.19 | 2024 | |
| Lundbeck LLC | $57.43 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $24.31 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $21.65 | 2021 | |
| Dexcom, INC. | $18.77 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $15.93 | 2024 | Zepbound |
| Currax Pharmaceuticals LLC | $14.14 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.